Terms ending in 2040
Every in-force patent on Chemocentryx, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,792,360 | Compositions and Methods for Treating Inflammatory Bowel Disease Using CCR9 Inhibitor and Anti-Tnf-Alpha Blocking Antibodies In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,608,336 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,986,466 | Methods of Treating Solid Tumors with CCR2 Antagonists In force · High confidence | The Regents of the University of California | In force | High confidence | |
| US 11,266,643 | Triaryl Compounds for Treatment of PD-L1 Diseases In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,533,354 | Triaryl Compounds for Treatment of PD-L1 Diseases In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,446,289 | Combination Therapy Using C-C Chemokine Receptor 4 (CCR4) Antagonists and One or More Immune Checkpoint Inhibitors In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,485,708 | Compounds for Treatment of PD-L1 Diseases In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 11,872,217 | Indanes as PD-L1 Inhibitors In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,371,433 | Heteroaryl-Biphenyl Amines for the Treatment of PD-L1 Diseases In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| US 12,497,383 | Heteroaryl-Biphenyl Amides for the Treatment of PD-L1 Diseases In force · High confidence | Chemocentryx, Inc. | In force | High confidence | |
| 2 more term ends in 2040 · Pro | |||||
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
11 of these are in force and held by Chemocentryx, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.